Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

Trial status: Authorised Evaluation of delayed adverse event(s) will be based on the occurrence of: New malignancy(ies); New incidence or exacerbation of a pre-existing neurologic disorder​; New incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder; New incidence of a hematologic disorder; New incidence of infection related to RPx​, New herpetic infection and presence of RPx detected in samples collected from herpetic lesions

Age group: 18-64 years, 65+ years Gender: Female, Male Target enrollment: 41 participants